BIOGEN INC. is 20.2x more valuable than NOVAVAX INC by market capitalization ($29.53 B vs $1.46 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NVAX | BIIB |
|---|---|---|
| Market cap | $1.46 B | $29.53 B |
| US-listed rank | #2366 | #476 |
| Revenue (latest FY) | $1.12B | $9.89B |
| Net income (latest FY) | $440.30M | $1.29B |
| Net margin | 39.2% | 13.1% |
| P/E (trailing FY) | 3.3 | 22.8 |
| SEC filings | 1,627 | 2,690 |
BIOGEN INC. is 20.2x more valuable than NOVAVAX INC by market capitalization ($29.53 B vs $1.46 B).
In their latest fiscal years, NOVAVAX INC reported $1.12B in revenue while BIOGEN INC. reported $9.89B.
Full pages: NOVAVAX INC and BIOGEN INC., or browse the full rankings.